CLINICAL TRIALS PROFILE FOR IMETELSTAT SODIUM
✉ Email this page to a colleague
All Clinical Trials for IMETELSTAT SODIUM
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00124189 ↗ | Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD) | Completed | Geron Corporation | Phase 1 | 2005-07-01 | The purpose of this study is to determine the safety and maximum tolerated dose of GRN163L in treating patients with refractory or relapsed chronic lymphoproliferative disease. |
NCT01256762 ↗ | Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer | Completed | Geron Corporation | Phase 2 | 2010-11-01 | The purpose of this study is to evaluate the efficacy and safety of treatment with imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) alone for patients with locally recurrent or metastatic breast cancer who have not received chemotherapy or have received one non-taxane based chemotherapy for metastatic breast cancer. |
NCT01265927 ↗ | A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer | Completed | Breast Cancer Research Foundation | Phase 1 | 2011-01-01 | A study to evaluate safety and biologic effects of giving GRN163L in combination with trastuzumab in patients diagnosed with HER2+ metastatic breast cancer that is resistant to therapy with trastuzumab. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for IMETELSTAT SODIUM
Condition Name
Clinical Trial Locations for IMETELSTAT SODIUM
Trials by Country
Clinical Trial Progress for IMETELSTAT SODIUM
Clinical Trial Phase
Clinical Trial Sponsors for IMETELSTAT SODIUM
Sponsor Name